We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Targeting Tumors: Challenges of Antibody-Drug Conjugates

Video   Jun 12, 2018 | Nature Video, YouTube

 

Treating cancer requires aggressive but targeted therapy. Some cancer drugs are too toxic because they damage healthy cells as well as tumor cells. So researchers are trying to develop ways to make sure drugs only target the right cells.

One solution is to attach drugs to antibodies specific to a protein expressed on tumor cells. These drugs are called antibody-drug conjugates (ADCs).

More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor. 


 
More Information
 
 
 

Recommended Videos

T Cell Actively Killing a Cancer Cell

Video

This incredible live footage shows a T cell actively killing a cancer cell.

WATCH NOW

Flow Cytometry Panel Builder

Video

This online tool guides you through flow cytometry panel design, providing a simplified, customizable experience to fit your flow cytometry panel design needs.

WATCH NOW

Webinar: Improving hepatocyte activity, pooling and lab efficiency

Video

CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows for distinct benefits to hepatocyte performance, efficiency in the lab, and test system design, precipitating the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods. This webinar will discuss the technology, its optimal utilization and benefits

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Biopharma Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE